FDA gives new Biogen Alzheimer's treatment priority status

An Alzheimer’s treatment developed by Biogen and a partner has been granted priority status by the FDA, giving it an accelerated approval process.


The FDA has granted US-based Biogen and Japanese firm Eisai priority status for another Alzheimer’s treatment, lecanemab.

That has rubbed off on Eisai’s share price, which increased by 6.9% to JPY 6226 on the Tokyo exchange.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs